Profusa stock analysis
Want to see PFSA full AI Analyst Report?
Profusa (PFSA) Stock Price & Analysis
PFSA Stock Chart & Stats
- Day’s Range
- $0.40 - $0.49
- 52-Week Range
- $0.40 - $1,539.09
- Previous Close
- $0.46
- Volume
- N/A
- Average Volume (3M)
- 2.05M
- Market Cap
- $271.33K
- Enterprise Value
- $13.96M
- Total Cash (Recent Filing)
- $339.00K
- Total Debt (Recent Filing)
- $6.47M
- Price to Earnings (P/E)
- ―
- Beta
- 1.20
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Biosensor Platform
The tissue-integrated sensor platform addresses continuous, real-time physiological monitoring through an implantable device and external reader. Its potential applications across health monitoring and performance tracking provide multiple commercialization pathways if the technology advances into broader product adoption.
Improved Capital Structure
Exchanging approximately $6.14 million of secured notes into preferred equity reduces the company’s secured debt burden and shifts a creditor claim toward equity exposure. That change can improve capital-structure flexibility and reduce immediate repayment pressure, although ownership concentration remains relevant.
Nasdaq Compliance Restored
Regaining compliance with Nasdaq’s bid-price and equity requirements preserves the company’s exchange listing and access to public-market infrastructure. Maintaining that status supports continued trading visibility and financing access, although the one-year monitoring period means compliance remains an ongoing requirement.
Bears Say
No Revenue And Widening Losses
The absence of reported revenue across periods indicates that commercialization has not yet produced measurable operating scale. At the same time, the much larger TTM loss shows deteriorating earnings performance, leaving the business dependent on future product progress and external capital to reach profitability.
Persistent Cash Burn
Deeply negative operating and free cash flow show that current activities consume cash rather than fund themselves. Continued cash burn limits internal reinvestment capacity and increases the need for financing while the company works toward commercialization, making execution and liquidity important medium-term constraints.
Secured Convertible Financing
The new secured convertible note demonstrates continued reliance on creditor financing and adds obligations that can restrict financial flexibility. Asset security prioritizes the lender, while equity conversion and stock-based interest or amortization payments create potential dilution for shareholders if additional funding remains necessary.
Profusa News
PFSA FAQ
What was Profusa’s price range in the past 12 months?
What is Profusa’s market cap?
When is Profusa’s upcoming earnings report date?
How were Profusa’s earnings last quarter?
Is Profusa overvalued?
Does Profusa pay dividends?
What is Profusa’s EPS estimate?
How many shares outstanding does Profusa have?
What happened to Profusa’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Profusa?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Profusa
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jack E. Stover
- Employees
- 2
- Website
- profusa.com
- Address
- 626 Bancroft Way, Suite A, Berkeley, CA, 94710, US
Profusa (PFSA) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 2 | 15 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 0 | 0 | 12 |












